FDA Gives Priority Review to Tovorafenib in Pediatric Low-Grade Glioma

News
Article

The FDA has set a Prescription Drug User Fee Act date of April 30, 2024 for tovorafenib as a treatment for pediatric patients with relapsed or progressive low-grade glioma.

Supporting data for the new drug application came from the phase 2 FIREFLY-1 trial (NCT04775485)assessing tovorafenib in patients with relapsed or progressive pediatric low-grade glioma.

Supporting data for the new drug application came from the phase 2 FIREFLY-1 trial (NCT04775485)assessing tovorafenib in patients with relapsed or progressive pediatric low-grade glioma.

The FDA has granted priority review to a new drug application (NDA) for single-agent tovorafenib (DAY101) as a treatment for those with relapsed or progressive pediatric, low-grade glioma, according to a press release from Day One Biopharmaceuticals.1

The regulatory agency has set a Prescription Drug User Fee Act date of April 30, 2024 for their review of tovorafenib in this indication.

“We are pleased to be one step closer to achieving our mission of bringing a novel targeted therapy to children whose low-grade gliomas with BRAF alterations have relapsed or progressed,” Jeremy Bender, PhD, chief executive officer at Day One, said in the press release.1 “We are grateful to the patients and their caregivers who participated in the FIREFLY-1 trial and look forward to continuing to collaborate with the FDA as we prepare to make this treatment more broadly available to those who need it.”

Supporting data for the NDA came from the phase 2 FIREFLY-1 trial (NCT04775485) assessing tovorafenib in patients with relapsed or progressive pediatric low-grade glioma. Updated data highlighted an overall response rate (ORR) of 67%—including a complete response rate of 17% and a partial response rate of 49%—and a clinical benefit rate of 93% among 69 evaluable patients per Response Assessment for Neuro-Oncology High-Grade Glioma (RANO-HGG) criteria.2 Additionally, investigators reported a median duration of response (DOR) of 16.6 months (95% CI, 11.6-not estimable) as of the data cutoff of June 5, 2023.

With respect to safety, most adverse effects (AEs) observed in the FIREFLY-1 trial were grade 1 or 2. The most common toxicities included hair color changes (76%), fatigue (44%), maculopapular rash (41%), dry skin (33%), and dermatitis acneiform (30%). Overall, investigators highlighted that tovorafenib was well tolerated among patients.

“We believe that tovorafenib, if approved, could change the treatment landscape for children living with this chronic and relentless disease,” Bender said in a press release at the time these data were published.2

In the open-label, multi-center FIREFLY-1 trial, patients received the oral pan-RAF inhibitor tovorafenib as an immediate-release tablet at 100 mg or as powder for reconstitution at 25 mg/mL.

The trial’s primary end point was ORR based on RANO-HGG criteria. Secondary and exploratory end points included ORR based on Response Assessment in Pediatric Neuro-Oncology Low-Grade Glioma (RAPNO-LGG) criteria, progression-free survival, safety, and quality of life.

Patients 6 months to 25 years old with relapsed or progressive low-grade glioma with known activating BRAF alterations, as well as locally advanced or metastatic solid tumors with an activated RAF fusion were able to enroll on the trial. Additional eligibility criteria included receiving at least 1 prior line of systemic therapy with evidence of radiographic progression and at least 1 measurable lesion based on RANO or RECIST v1.1 guidelines.

The FDA granted a rare pediatric disease designation for tovorafenib in pediatric low-grade glioma in July 2021.3

References

  1. Day One announces FDA acceptance of NDA and priority review for tovorafenib in relapsed or progressive pediatric low-grade glioma (pLGG). News release. Day One Biopharmaceuticals. October 30, 2023. Accessed October 31, 2023. https://shorturl.at/mOS13
  2. Day One announces updated FIREFLY-1 data for tovorafenib and completion of rolling NDA submission to FDA for relapsed or progressive pediatric low-grade glioma (pLGG). News release. Day One Pharmaceuticals. September 11, 2023. Accessed October 31, 2023. https://shorturl.at/zBCQX
  3. Day One receives FDA rare pediatric disease designation for DAY101 for the treatment of pediatric low-grad glioma. News Release. Day One Pharmaceuticals. July 27, 2021. Accessed October 31, 2023. https://bit.ly/2THrHUi
Recent Videos
Raymond B. Mailhot, MD, MPH, discussed how radiation therapy can impact education and survivorship for pediatric survivors of brain tumors.
Significant results from a retrospective analysis of brain tumor survivor academic performance after radiotherapy emerged despite small sampling size.
Raymond B. Mailhot, MD, MPH, discussed methods for comparing academic performances of patients following radiation therapy with healthy control groups.
The act of asking for help is critical to finding mentors who can help one advance in the brain cancer field, according to Yoshie Umemura, MD.
Through multidisciplinary collaboration, Yoshie Umemura, MD, and colleagues were able to organize the Gliofocus trial in brain cancer relatively fast.
Yoshie Umemura, MD, discusses how multiple departments can positively impact a patient with brain cancer during their visit to a medical center.
Antibody-drug conjugates and small molecule inhibitors may show utility in the neuro-oncology field, according to Nader Sanai, MD.
The phase 3 Gliofocus trial aims to meaningfully improve survival and quality of life with niraparib among patients with newly diagnosed glioblastoma.
Findings from a proof-of-concept study show a potential survival benefit with niraparib/radiotherapy in patients with newly diagnosed glioblastoma.
ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.
Related Content
Patients with newly diagnosed glioblastoma had improved survival when treated with TTFields plus temozolomide and pembrolizumab.

TTFields Plus Temozolomide/Pembrolizumab Controls Tumors in Glioblastoma

Ariana Pelosci
November 11th 2024
Article

Patients with newly diagnosed glioblastoma had improved survival when treated with TTFields plus temozolomide and pembrolizumab.

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

Forming Connections and Making a Difference in the Brain Cancer Field

Yoshie Umemura, MD
October 7th 2024
Podcast

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

The expanded approval of methotrexate may offer a convenient alternative to pediatric patients who have difficulty swallowing pills.

FDA Expands Approval for Methotrexate in Pediatric ALL, pJIA Indications

Russ Conroy
October 29th 2024
Article

The expanded approval of methotrexate may offer a convenient alternative to pediatric patients who have difficulty swallowing pills.

Investigators of the Gliofocus trial look to set a clinically relevant “benchmark” in the glioblastoma field, according to Nader Sanai, MD.

Advancing Glioblastoma Research Through a Phase 3 Niraparib Trial

Nader Sanai, MD
September 23rd 2024
Podcast

Investigators of the Gliofocus trial look to set a clinically relevant “benchmark” in the glioblastoma field, according to Nader Sanai, MD.

Investigators are assessing the feasibility, safety, and efficacy of MTX110 for patients with recurrent glioblastoma as part of the phase 1 MAGIC-1 study.

MTX110 May Show Survival Benefits in Recurrent Glioblastoma

Russ Conroy
October 20th 2024
Article

Investigators are assessing the feasibility, safety, and efficacy of MTX110 for patients with recurrent glioblastoma as part of the phase 1 MAGIC-1 study.

Efficacy findings were enhanced when 177Lu-Dotatate was used to treat patients with grade II/III recurrent meningioma.

177Lu-Dotatate Improves PFS in Recurrent Meningioma

Ariana Pelosci
October 1st 2024
Article

Efficacy findings were enhanced when 177Lu-Dotatate was used to treat patients with grade II/III recurrent meningioma.